Literature DB >> 27378758

Chapter Five - Ubiquitination of Ion Channels and Transporters.

S M Lamothe1, S Zhang2.   

Abstract

Ion channels and transporters play essential roles in excitable cells including cardiac, skeletal, and smooth muscle cells, neurons, and endocrine cells. Their dysfunction underlies the pathology of various diseases. Thus, the tight regulation of these transmembrane proteins is essential for cell physiology. While the ubiquitin system is involved in many aspects of cellular processes, this chapter focuses on the ubiquitin-mediated degradation of ion channels and transporters. Ubiquitination of ion channels and transporters is multifaceted and occurs at various cellular compartments such as the plasma membrane and the endoplasmic reticulum. While various molecules are involved in the ubiquitination of ion channels and transporters, E3 ubiquitin ligases play a central role in selectively targeting substrates for ubiquitination and will be a major focus in this chapter. To date, the Nedd4 family of E3 ubiquitin ligases and their regulations of ion channels and transporters have been extensively studied. In this chapter, we will first review Nedd4/Nedd4-2 and their regulations. We will then discuss how E3 ubiquitin ligases, especially Nedd4-2, regulate various ion channels and transporters including epithelial Na(+) channels, voltage-gated Na(+) channels, KCNQ and hERG K(+) channels, Cl(-) channels such as CFTR, transporters such as Na(+)/K(+) ATPase, and gap junctions. Furthermore, diseases caused by improper ubiquitination of ion channels and transporters will be discussed to highlight the process of ubiquitination and its biological as well as clinical significance.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cl(−) channel; Gap junction; K(+) channel; Na(+) channel; Nedd4-2; ion channel; transporter

Mesh:

Substances:

Year:  2016        PMID: 27378758     DOI: 10.1016/bs.pmbts.2016.02.005

Source DB:  PubMed          Journal:  Prog Mol Biol Transl Sci        ISSN: 1877-1173            Impact factor:   3.622


  6 in total

1.  Mg2+ restriction downregulates NCC through NEDD4-2 and prevents its activation by hypokalemia.

Authors:  Mohammed Z Ferdaus; Anindit Mukherjee; Jonathan W Nelson; Philip J Blatt; Lauren N Miller; Andrew S Terker; Olivier Staub; Dao-Hong Lin; James A McCormick
Journal:  Am J Physiol Renal Physiol       Date:  2019-07-31

2.  Targeted Degradation of SLC Transporters Reveals Amenability of Multi-Pass Transmembrane Proteins to Ligand-Induced Proteolysis.

Authors:  Ariel Bensimon; Mattia D Pizzagalli; Felix Kartnig; Vojtech Dvorak; Patrick Essletzbichler; Georg E Winter; Giulio Superti-Furga
Journal:  Cell Chem Biol       Date:  2020-05-07       Impact factor: 8.116

3.  Multiubiquitination of TRPV4 reduces channel activity independent of surface localization.

Authors:  William H Aisenberg; Brett A McCray; Jeremy M Sullivan; Erika Diehl; Lauren R DeVine; Jonathan Alevy; Anna M Bagnell; Patrice Carr; Jack K Donohue; Benedikt Goretzki; Robert N Cole; Ute A Hellmich; Charlotte J Sumner
Journal:  J Biol Chem       Date:  2022-03-14       Impact factor: 5.486

4.  Pharmacological suppression of Nedd4-2 rescues the reduction of Kv11.1 channels in pathological cardiac hypertrophy.

Authors:  Hua Zhang; Tian Fu; Jinglei Sun; Sihao Zou; Suhua Qiu; Jiali Zhang; Shi Su; Chenxia Shi; De-Pei Li; Yanfang Xu
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

Review 5.  The Kv10.1 Channel: A Promising Target in Cancer.

Authors:  Enoch Luis; Arely Anaya-Hernández; Paulina León-Sánchez; María Luisa Durán-Pastén
Journal:  Int J Mol Sci       Date:  2022-07-30       Impact factor: 6.208

6.  The SGK3-triggered ubiquitin-proteasome degradation of podocalyxin (PC) and ezrin in podocytes was associated with the stability of the PC/ezrin complex.

Authors:  Ya-Pei Yuan; Hong Zhao; Li-Qin Peng; Zi-Fang Li; Song Liu; Cheng-Yan Yuan; Mercy-Julian Mwamunyi; David Pearce; Li-Jun Yao
Journal:  Cell Death Dis       Date:  2018-11-01       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.